National Institutes of Health to Consider Exclusive Patent License to Inversago Pharma for Rare Diseases

Summary

The National Heart, Lung and Blood Institute and the National Human Genome Research Institute are considering granting an exclusive patent license to Inversago Pharma, a Canadian company, to develop treatments for Hermansky-Pudlak Syndrome and Idiopathic Pulmonary Fibrosis, two rare diseases.